Literature DB >> 11248815

Changing indications for penetrating keratoplasty in Taiwan from 1987 to 1999.

W L Chen1, F R Hu, I J Wang.   

Abstract

PURPOSE: To determine the leading indications for penetrating keratoplasty and to identify changing trends in these indications during the past 12 years.
METHODS: We retrospectively performed a chart review of the hospital records of all patients undergoing penetrating keratoplasty at the National Taiwan University Hospital during a 12-year period (1987-1999). When possible, the clinical indication was corroborated by the pathologic report.
RESULTS: A total of 770 corneal transplants were performed. The leading indications for penetrating keratoplasty. in order of decreasing frequency, were corneal scars (27.9%), regraft (21.0%), acute necrotizing and ulcerative keratitis (17.9%), pseudophakic or aphakic bullous keratopathy (17.6%), Fuchs' dystrophy (4.5%), and keratoconus (2.5%). A trend of increasing frequency of regraft and acute necrotizing and ulcerative keratitis, a decreasing frequency of corneal scar, and an initially decreasing then increasing frequency of pseudophakic and aphakic bullous keratopathy were found during the 12-year study period. Acute necrotizing and ulcerative keratitis was found to be the most frequent indication for regraft.
CONCLUSION: In this series, corneal scars, regraft, and acute necrotizing and ulcerative keratitis were the leading indications for penetrating keratoplasty. A changing incidence of pseudophakic and aphakic bullous keratopathy noted during the study period was related to the type of intraocular lens implanted and the method of cataract surgery performed. This study found a comparatively high frequency of acute necrotizing and ulcerative keratitis and an extremely low frequency of keratoconus compared with previous reports.

Entities:  

Mesh:

Year:  2001        PMID: 11248815     DOI: 10.1097/00003226-200103000-00004

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  24 in total

1.  Indications for penetrating keratoplasty in East China, 1994-2003.

Authors:  Chaoran Zhang; Jianjiang Xu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

2.  Exfoliative epitheliopathy of bullous keratopathy with breaches in the MUC16 Glycocalyx.

Authors:  Ben J Glasgow; Oktay K Gasymov; Richard C Casey
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-06       Impact factor: 4.799

3.  Fuchs' corneal dystrophy.

Authors:  Allen O Eghrari; John D Gottsch
Journal:  Expert Rev Ophthalmol       Date:  2010-04

4.  Penetrating keratoplasty for keratoconus: visual and graft survival outcomes.

Authors:  Mansour M Al-Mohaimeed
Journal:  Int J Health Sci (Qassim)       Date:  2013-01

5.  Indications for and techniques of keratoplasty at Vietnam National Institute of Ophthalmology.

Authors:  Pham Ngoc Dong; Truong Nhu Han; Anthony J Aldave; Hoang Thi Minh Chau
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

6.  Indications of penetrating keratoplasty in southern India.

Authors:  Laxman Dasar; Chaitra Pujar; Kanwarpal Singh Gill; Madhuri Patil; Mallikarjun Salagar
Journal:  J Clin Diagn Res       Date:  2013-11-10

7.  Trends in the indications for penetrating keratoplasty in Shandong, 2005-2010.

Authors:  Jun-Yi Wang; Li-Xin Xie; Xiu-Sheng Song; Jing Zhao
Journal:  Int J Ophthalmol       Date:  2011-10-18       Impact factor: 1.779

8.  Tear lipocalin captures exogenous lipid from abnormal corneal surfaces.

Authors:  Ben J Glasgow; Oktay K Gasymov; Adil R Abduragimov; Jamison J Engle; Richard C Casey
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-03       Impact factor: 4.799

Review 9.  Genetics of corneal endothelial dystrophies.

Authors:  Chitra Kannabiran
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

Review 10.  Graft failure: III. Glaucoma escalation after penetrating keratoplasty.

Authors:  Emily C Greenlee; Young H Kwon
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.